Ahmara Ross, MD, PhD, Assistant Professor of Ophthalmology and Neurology at Penn Medicine
Olena Korsun, RN, BSN, LPC, Psychiatric Nurse at Fairmount Behavioral Health
This online event is free to join but donations to VSCâs endowment fund are greatly appreciated.
About VSC
Our mission is to provide advocacy and counseling for all who have been affected by sexual violence and other crimes against the person and to promote sensitivity and awareness in the community through education. Founded in 1974 as Women Against Rape, VSC expanded to serve victims of other crimes and child abuse. VSC has been supporting survivors and their families for more than 47 years. Victim Services of Montgomery County, Inc. is a 501(c)(3) nonprofit organization. VSCâs free, 24-hour hotline can be reached at 1-888-521-0983.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases
December 18, 2020 GMT
LONDON (BUSINESS WIRE) Dec 18, 2020
Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead to permanent vision loss. Gyroscope has an exclusive option to the intellectual property associated with, and arising from, the research conducted under the agreement.
Dec 18, 2020 06:00 UTC
Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases LONDON (Business Wire) Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead to permanent vision loss. Gyroscope has an exclusive option to the intellectual property associated with, and arising from, the research conducted under the agreement.
A team of researchers from CAROT and Gyroscope will work together to explore specific gene therapy targets for glaucoma, optic neuritis and retinitis pigmentosa. The CAROT team is led by Jean Bennett, M.D., Ph.D., the F.M. Kirby Professor of Ophthalmology, along with Ken Shindler, M.D., Ph.D.,